Molecular structure of Potassium canrenoate, CAS Number: 2181-04-6
Potassium canrenoate (CAS 2181-04-6)
Alternate Names:
Canrenoic acid potassium salt; Soldactone; Potassium aldadiene
Application:
Potassium canrenoate is a competitive aldosterone antagonist
CAS Number:
2181-04-6
Purity:
≥98%
Molecular Weight:
396.56
Molecular Formula:
C22H29O4•K
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Potassium canrenoate is a competitive aldosterone antagonist. It may act to counteract the effects of aldosterone-induced blood pressure increases in animals with high sodium intake. Potassium canrenoate is clinically used for its anti-fibrotic effects and may act to reduce cardiovascular fibrosis in animal models. At higher concentrations, however, potassium canrenoate has been found to produce genotoxic effects to the liver and an increase in tumor incidence studies with rodents.
Potassium canrenoate (CAS 2181-04-6) References
- Genotoxicity testing of potassium canrenoate in cultured rat and human cells. | Martelli, A., et al. 1999. Mutagenesis. 14: 463-72. PMID: 10473649
- Potassium canrenoate, an aldosterone receptor antagonist, reduces isoprenaline-induced cardiac fibrosis in the rat. | Bos, R., et al. 2004. J Pharmacol Exp Ther. 309: 1160-6. PMID: 14764658
- Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay. | Dasgupta, A., et al. 2008. Ther Drug Monit. 30: 744-7. PMID: 18824952
- Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay. | Dasgupta, A. and Johnson, MJ. 2010. J Clin Lab Anal. 24: 413-7. PMID: 21089173
- Population pharmacokinetic model of canrenone after intravenous administration of potassium canrenoate to paediatric patients. | Suyagh, M., et al. 2012. Br J Clin Pharmacol. 74: 864-72. PMID: 22376078
- Potassium canrenoate treatment in paediatric patients: a population pharmacokinetic study using novel dried blood spot sampling. | Suyagh, M., et al. 2013. J Hypertens. 31: 1901-8. PMID: 23846862
- Electrophysiological and antiarrhythmic properties of potassium canrenoate during myocardial ischemia-reperfusion. | Alexandre, J., et al. 2015. J Cardiovasc Pharmacol Ther. 20: 313-21. PMID: 25389106
- Antihypertensive effect of captopril, canrenoate potassium, and atenolol. Relations with red blood cell sodium transport and renin. | Niutta, E., et al. 1988. Am J Hypertens. 1: 364-71. PMID: 3063286
- Potassium canrenoate compounding for administration via enteral feeding tubes: a physical and microbiological stability study. | Logrippo, S., et al. 2018. Eur J Hosp Pharm. 25: e120-e125. PMID: 31157081
- Patients with acute heart failure treated with the CARRESS-HF diuretic protocol in association with canrenoate potassium: Tolerance of high doses of canrenoate potassium. | Berger, C., et al. 2020. Arch Cardiovasc Dis. 113: 679-689. PMID: 32948466
- Mineralocorticoid Receptor Antagonist Use and Hard Renal Outcomes in Real-World Patients With Chronic Kidney Disease. | Oka, T., et al. 2022. Hypertension. 79: 679-689. PMID: 35026955
- Mineralocorticoid Receptor Antagonist (Potassium Canrenoate) Does Not Influence Outcome in the Treatment of COVID-19-Associated Pneumonia and Fibrosis-A Randomized Placebo Controlled Clinical Trial. | Kotfis, K., et al. 2022. Pharmaceuticals (Basel). 15: PMID: 35215312
- Dexamethasone and potassium canrenoate alleviate hyperalgesia by competitively regulating IL-6/JAK2/STAT3 signaling pathway during inflammatory pain in vivo and in vitro. | Liu, J., et al. 2022. Immun Inflamm Dis. 10: e721. PMID: 36301041
- Positive inotropic effect of K-canrenoate: an investigation in anaesthetized dogs, untreated or treated with digitalis. | Marchetti, G., et al. 1983. Arch Int Pharmacodyn Ther. 266: 250-63. PMID: 6667069
- Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. | Angeli, P., et al. 1994. Hepatology. 19: 72-9. PMID: 8276370
Inhibitor of:
Aldosterone.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Potassium canrenoate, 1 g | sc-205812 | 1 g | $54.00 | |||
Potassium canrenoate, 5 g | sc-205812A | 5 g | $131.00 |